First Turn Management LLC Lowers Position in Disc Medicine, Inc. $IRON

First Turn Management LLC trimmed its stake in Disc Medicine, Inc. (NASDAQ:IRON) by 61.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 153,206 shares of the company’s stock after selling 244,487 shares during the quarter. First Turn Management LLC’s holdings in Disc Medicine were worth $12,166,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. grew its holdings in Disc Medicine by 2.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,094 shares of the company’s stock valued at $469,000 after purchasing an additional 138 shares during the period. Arizona State Retirement System lifted its position in Disc Medicine by 2.2% during the fourth quarter. Arizona State Retirement System now owns 6,798 shares of the company’s stock valued at $540,000 after buying an additional 144 shares in the last quarter. Police & Firemen s Retirement System of New Jersey lifted its position in Disc Medicine by 3.3% during the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 6,716 shares of the company’s stock valued at $533,000 after buying an additional 215 shares in the last quarter. Avanza Fonder AB lifted its position in Disc Medicine by 14.1% during the fourth quarter. Avanza Fonder AB now owns 1,903 shares of the company’s stock valued at $151,000 after buying an additional 235 shares in the last quarter. Finally, Kennedy Capital Management LLC lifted its position in Disc Medicine by 3.3% during the fourth quarter. Kennedy Capital Management LLC now owns 9,324 shares of the company’s stock valued at $740,000 after buying an additional 296 shares in the last quarter. 83.70% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Wells Fargo & Company lifted their price target on shares of Disc Medicine from $78.00 to $79.00 and gave the company an “overweight” rating in a research report on Monday, March 2nd. Cantor Fitzgerald reduced their price target on shares of Disc Medicine from $153.00 to $125.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 17th. Wall Street Zen raised shares of Disc Medicine from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. Morgan Stanley lifted their price target on shares of Disc Medicine from $75.00 to $80.00 and gave the company an “overweight” rating in a research report on Thursday, May 14th. Finally, Wedbush reissued an “outperform” rating and set a $88.00 target price on shares of Disc Medicine in a research report on Wednesday. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Disc Medicine has an average rating of “Moderate Buy” and an average target price of $105.30.

Disc Medicine Trading Down 0.1%

NASDAQ IRON opened at $67.99 on Friday. The company’s fifty day simple moving average is $68.16 and its 200-day simple moving average is $72.57. Disc Medicine, Inc. has a 52 week low of $40.00 and a 52 week high of $99.50. The company has a current ratio of 24.00, a quick ratio of 24.00 and a debt-to-equity ratio of 0.04. The stock has a market cap of $2.59 billion, a P/E ratio of -10.27 and a beta of 0.93.

Disc Medicine (NASDAQ:IRON) last posted its earnings results on Tuesday, May 5th. The company reported ($1.65) EPS for the quarter, missing analysts’ consensus estimates of ($1.62) by ($0.03). Equities research analysts predict that Disc Medicine, Inc. will post -6.74 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Jean M. Franchi sold 6,257 shares of the business’s stock in a transaction on Tuesday, April 14th. The shares were sold at an average price of $69.24, for a total transaction of $433,234.68. Following the transaction, the chief financial officer directly owned 64,333 shares of the company’s stock, valued at approximately $4,454,416.92. The trade was a 8.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider William Jacob Savage sold 5,731 shares of the business’s stock in a transaction on Monday, April 13th. The stock was sold at an average price of $66.38, for a total transaction of $380,423.78. Following the transaction, the insider directly owned 79,480 shares in the company, valued at approximately $5,275,882.40. The trade was a 6.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 12,388 shares of company stock worth $841,258. Corporate insiders own 3.76% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.